Trials / Completed
CompletedNCT03942120
Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab)
Post-Marketing Surveillance for Crohn's Disease Patients Treated With STELARA
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 685 (actual)
- Sponsor
- Janssen Korea, Ltd., Korea · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of post-marketing surveillance (PMS) is to assess the safety and effectiveness of ustekinumab (Stelara) for Crohn's disease participants under real world clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ustekinumab | Participants treated with ustekinumab under real world clinical practice will be observed in this study. No study drug will be administered as a part of this study. |
Timeline
- Start date
- 2019-04-08
- Primary completion
- 2022-01-14
- Completion
- 2022-01-14
- First posted
- 2019-05-08
- Last updated
- 2025-04-27
Locations
43 sites across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03942120. Inclusion in this directory is not an endorsement.